• Users Online: 705
  • Print this page
  • Email this page
Year : 2012  |  Volume : 5  |  Issue : 3  |  Page : 345-349

Caffeine therapy for apnoea of prematurity in very low-birthweight infants

1 Department of Pediatrics and Centre for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine; Children's Hospital of Philadelphia, Philadelphia, PA, , and Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada, USA
2 Department of Paediatrics, University of Toronto, and Mount Sinai Hospital, Toronto, Ontario, Canada
3 Departments of Obstetrics and Gynaecology and Paediatrics, University of Melbourne, and Royal Women's Hospital, Melbourne, Australia

Correspondence Address:
Barbara Schmidt
Division of Neonatology, Ravdin 8, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.7707/hmj.v5i3.190

Rights and Permissions

Caffeine and other methylxanthines have been used to treat apnoea of prematurity for over 30 years. However, until recently, experimental evidence of the potential harm and lack of rigorous evaluation of this drug therapy in controlled clinical trials resulted in substantial uncertainty about the safety of the routine use of methylxanthines in preterm infants. The international Caffeine for Apnoea of Prematurity (CAP) trial group was formed in 1998. This collaborative research team enrolled over 2000 very low-birthweight infants in North America, Australia and Europe, and followed the children to the end of their second year of life. The CAP trial investigators showed for the first time that neonatal caffeine therapy reduces the rates of important short- and long-term morbidities such as bronchopulmonary dysplasia, severe retinopathy of prematurity, cerebral palsy and cognitive delay. Of all the neonatal treatments that have been subjected to economic evaluations, caffeine therapy is the most certain to be both cost saving and beneficial. It is therefore imperative that responsible drug manufacturers make safe and affordable formulations of caffeine available worldwide.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded58    
    Comments [Add]    
    Cited by others 1    

Recommend this journal